Ceftobiprole Medocaril Is an Effective Post-Exposure Treatment in the Fischer 344 Rat Model of Pneumonic Tularemia

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Francisella tularensis subspecies tularensis is a Category A biothreat agent causing lethal tularemia.
• Pneumonic tularemia presents a significant public health risk, necessitating effective medical countermeasures.
• Ceftobiprole medocaril is an investigational antibiotic with potential therapeutic applications.

Purpose of the Study:

• To evaluate the efficacy of ceftobiprole medocaril against inhalational tularemia caused by Francisella tularensis subspecies tularensis.
• To determine the survival rates and bacterial burden in a rat model following treatment with ceftobiprole medocaril.
• To compare the efficacy of ceftobiprole medocaril with levofloxacin and placebo treatments.

Main Methods:

• Fischer 344 rats were infected via inhalation with Francisella tularensis subspecies tularensis.
• Animals were treated with ceftobiprole medocaril, levofloxacin, or placebo.
• Survival rates, body weights, and bacterial loads in blood, liver, lung, and spleen were monitored.

Main Results:

• Ceftobiprole medocaril treatment resulted in a 92% survival rate at 31 days post-challenge, comparable to levofloxacin.
• Placebo-treated rats experienced 100% mortality, confirming the lethal nature of the infection.
• No detectable bacterial infection was found in surviving rats treated with ceftobiprole medocaril or levofloxacin.

Conclusions:

• Ceftobiprole medocaril is efficacious in treating inhalational tularemia caused by Francisella tularensis subspecies tularensis in a rat model.
• The antibiotic provides a promising therapeutic option for pneumonic tularemia, a critical biothreat.
• Further investigation into ceftobiprole medocaril as a medical countermeasure is warranted.